PDF下载 ( 2657 KB)
Prognostic accuracy of staging systems in patients with primary liver cancer treated with transarterial chemoembolization
-
摘要: 目的探索肝癌肝动脉化疗栓塞术（TACE）术后患者预后评价的有效分期。方法回顾性分析2006年9月至2009年5月间行TACE治疗的原发性肝癌患者的临床随访资料,比较CTP分级、MELD评分、Okuda分期、BCLC分级、CS分期和Tokyo评分对TACE治疗后生存情况的预测能力的差异。结果 Kaplan-Meier生存曲线及log-rank检验结果显示,Okuda分期各期别间差异均有统计学意义（ⅠvsⅡP=0.013,ⅡvsⅢP<0.001）;BCLC分级B级与C级间差异有统计学意义（P=0.008）;CS分期Ⅱ期同Ⅲ期之间差异具有统计学意义（P=0.001）。Cox多因素回归分析得到Okuda分期（P=0.039）、BCLC分级（P=0.022）有统计学意义。BCLC分级同时具有最小的-2Ln（L）、AIC、SBC值,分别为205.419、209.419、212.586。结论 BCLC分级对TACE治疗后的生存情况具有较好的预测作用,可能有助于选择适宜行TACE治疗的患者。Abstract: Objective To compare the performance of 6 available prognostic staging systems in predicting the survival of patients with primary liver cancer treated with TACE.Methods The clinical data of patients who had been diagnosed as liver cancer in our department from September 2006 to May 2009 were retrospectively analyzed to compare the CTP classification, the MELD scoring, the BCLC classification system, the CS staging system and the Tokyo scoring.Results The survival curves and log-rank test shows statistical significance in all stages of the Okuda staging system (Ⅰvs Ⅱ P=0.013, Ⅱvs Ⅲ P<0.001) , between stage B and C of the BCLC classification system (P=0.008) and between stage II and III of the CS staging system (P=0.001) .By the multiple factor regression method, the Okuda staging system (P=0.039) and the BCLC classification (P=0.022) also show a stronger significance on the prognosis.And the BCLC classification system is superior to the other staging systems with the minimum value of-2Ln (L) (205.419) , AIC (209.419) , SBC (212.586) .Conclusion The BCLC classification system provides the best prognostic stratification for a cohort of the patients with liver cancer treated with transarterial chemoembolization.
-
Key words:
- liver neoplasms /
- hepatic artery /
- chemoembolization
-
[1]Marelli L, Stigliano R, Triantos C, et al.Transarterial therapyfor hepatocellular carcinoma:which technique is moreeffective?A systematic review of cohort and randomizedstudies[J].Cardiovasc Intervent Radiol, 2007, 30 (1) :6-25. [2]中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324. [3]Kim JH, Kim JIH, Choi JH, et al.Value of the model for end-stageliver disease for predicting survival in hepatocellular carcinomapatients treated with transarterial chemoembolization[J].Scand JGastroenterol, 2009, 44 (3) :346-357. [4]Cho YK, Chung JW, Kim JK, et al.Comparison of 7 staging systemsfor patients with hepatocellular carcinoma undergoing transarterialchemoembolization[J].Cancer, 2008, 112 (2) :352-361. [5]Georgiades CS, Liapi E, Frangakis C, et al.Prognostic accuracy of12 liver staging systems in patients with unresectable hepatocellularcarcinoma treated with transarterial chemoembolization[J].J VascInterv Radiol, 2006, 17 (10) :1619-1624. [6]李怀波, 张振清, 戴函碧, 等.肝癌患者介入治疗后长期生存的综合分析[J].中国医学影像技术, 2009, 25 (12) :2286-2289. [7]张晓勇.肝动脉化疗栓塞治疗原发性肝癌的疗效及预后多因素分析[J].实用预防医学, 2009, 16 (3) :872-873. [8]罗懿忠, 区金锐.TNM分期评价肝癌术后TACE及预后的价值[J].广东医学, 2009, 30 (11) :1701-1703. [9]Chen CH, Hu FC, Huang GT, et al.Applicability of stagingsystems for patients with hepatocellular carcinoma isdependent on treatment method-Analysis of 2010 Taiwanesepatients[J].Eur J Cancer, 2009, 45 (1) :1630-1639. [10]Bruix J, Sherman M, Llovet JM, et al.Clinical managementof hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL Conference[J].J Hepatol, 2001, 35 (3) :421-430. [11]Cillo U, Bassanello M, Vitale A, et al.The critical issue ofhepatocellular carcinoma prognostic classification:which isthe best tool available?[J].J Hepatol, 2004, 40 (1) :124-131. [12]Llovet JM, Bru C, Bruix J.Prognosis of hepatocelluarcarcinoma:BCLC staging classification[J].Semin LiverDis, 1999, 19 (3) :329-337 [13]Llovet JM, Burroughs A, Bruix J.Hepatocellular carcinoma[J].Lancet, 2003, 362 (9399) :1907-1917. -
本文二维码
计量
- 文章访问数: 5520
- HTML全文浏览量: 7
- PDF下载量: 1553
- 被引次数: 0
下载:
